4-Acetamido-2-butenoic acid | 64120-63-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-Acetamido-2-butenoic acid
• 英文别名: (E)-4-acetamidobut-2-enoic acid
• CAS: 64120-63-4
• 化学式: C₆H₉NO₃
• 分子量: 143.14
• InChiKey: FFMCJGYZAHPFJO-NSCUHMNNSA-N

物化性质

• 沸点：
  439.4±38.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• KRAS G12C INHIBITORS
  申请人：Mirati Therapeutics, Inc.

  公开号：US20190144444A1

  公开（公告）日：2019-05-16

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别地，本发明涉及不可逆抑制KRas G12C活性的化合物、包含这些化合物的药物组合物及其使用方法。
• Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods
  申请人：Northwestern University

  公开号：US10273208B2

  公开（公告）日：2019-04-30

  Disclosed are methods for preparing and screening for an inhibitor of the activity of a biological molecule having a catalytic or non-catalytic cysteine residue. The methods including preparing a library of candidate inhibitor molecules by conjugating an electrophile to a plurality of drug molecules where the library of candidate inhibitor molecules thus formed react with cysteine residues. The library of candidate inhibitor molecules then may be reacted with the biological molecule to identify those inhibitor molecule that react with the catalytic or non-catalytic cysteine residue of the biological molecule in order to identify an inhibitor of the biological molecule.

  本发明公开了制备和筛选具有催化或非催化半胱氨酸残基的生物分子活性抑制剂的方法。这些方法包括制备候选抑制剂分子库，方法是将亲电子体与多个药物分子共轭，由此形成的候选抑制剂分子库与半胱氨酸残基发生反应。然后可将候选抑制剂分子库与生物分子反应，以确定那些与生物分子的催化或非催化半胱氨酸残基反应的抑制剂分子，从而确定生物分子的抑制剂。
• KRas G12C inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US10689377B2

  公开（公告）日：2020-06-23

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制 KRas G12C 的化合物。特别是，本发明涉及不可逆地抑制 KRas G12C 活性的化合物、包含该化合物的药物组合物及其使用方法。
• SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20160016893A1

  公开（公告）日：2016-01-21

  Disclosed are methods for screening for the binding affinity of chemical entities to other bioactive molecules. The screened chemical entities may be utilized in pharmaceutical composition or therapeutic methods for treating disease or disorders associated with the bioactive molecules including NEDD4-1.
• US9586890B2
  申请人：——

  公开号：US9586890B2

  公开（公告）日：2017-03-07